The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Role of Hyperphosphatemia and 1,25-Dihydroxyvitamin D in Vascular Calcification and Mortality in Fibroblastic Growth Factor 23 Null Mice
Abstract
Fibroblastic growth factor 23 (FGF23) regulates renal phosphate reabsorption and 1alpha-hydroxylase activity. Ablation of FGF23 results in elevated serum phosphate, calcium, and 1,25-dihydroxyvitamin D3 [1,25(OH)(2)D] levels; vascular calcifications; and early death. For determination of the independent roles of hyperphosphatemia and excess vitamin D activity on the observed phenotypic abnormalities, FGF23 null mice were fed a phosphate- or vitamin D-deficient diet. The phosphate-deficient diet corrected the hyperphosphatemia, prevented vascular calcifications, and rescued the lethal phenotype in FGF23 null mice, despite persistent elevations of serum 1,25(OH)(2)D and calcium levels. This suggests that hyperphosphatemia, rather than excessive vitamin D activity, is the major stimulus for vascular calcifications and contributes to the increased mortality in the FGF23-null mouse model. In contrast, the vitamin D-deficient diet failed to correct either the hyperphosphatemia or the vascular calcifications in FGF23 null mice, indicating that FGF23 independently regulates renal phosphate excretion and that elevations in 1,25(OH)(2)D and calcium are not sufficient to induce vascular calcifications in the absence of hyperphosphatemia. The vitamin D-deficient diet also improved survival in FGF23 null mice in association with normalization of 1,25(OH)(2)D and calcium levels and despite persistent hyperphosphatemia and vascular calcifications, indicating that excessive vitamin D activity can also have adverse effects in the presence of hyperphosphatemia and absence of FGF23. Understanding the independent and context-dependent interactions between hyperphosphatemia and excessive vitamin D activity, as well as vascular calcifications and mortality in FGF23 null mice, may ultimately provide important insights into the management of clinical disorders of hyperphosphatemia and excess vitamin D activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
Mineral Metabolism, Mortality, and Morbidity in Maintenance Hemodialysis
Block, G. A., Klassen, P. S., Lazarus, J. M., Ofsthun, N., Lowrie, E. G., & Chertow, G. M. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000133041.27682.a2 · Cited by 2,687
London, G. M. (2003) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg414 · Cited by 1,859
Shimada, T., Kakitani, M., Yamazaki, Y., Hasegawa, H., Takeuchi, Y., Fujita, T., Fukumoto, S., Tomizuka, K., & Yamashita, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19081 · Cited by 1,596
Goodpasture syndrome during the course of a Schönlein-Henoch purpura
Carreras, L., Poveda, R., Bas, J., Mestre, M., Rama, I., & Carrera, M. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.32799 · Cited by 1,474
Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients
Chertow, G. M., Burke, S. K., Raggi, P., & for the Treat to Goal Working Group (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00434.x · Cited by 1,462
Regulation of Fibroblast Growth Factor-23 Signaling by Klotho
Kurosu, H., Ogawa, Y., Miyoshi, M., Yamamoto, M., Nandi, A., Rosenblatt, K. P., Baum, M. G., Schiavi, S., Hu, M.-C., Moe, O. W., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.c500457200 · Cited by 1,366
Survival of Patients Undergoing Hemodialysis with Paricalcitol or Calcitriol Therapy
Teng, M., Wolf, M., Lowrie, E., Ofsthun, N., Lazarus, J. M., & Thadhani, R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022536 · Cited by 927
Kalantar-Zadeh, K., Kuwae, N., Regidor, D. L., Kovesdy, C. P., Kilpatrick, R. D., Shinaberger, C. S., McAllister, C. J., Budoff, M. J., Salusky, I. B., & Kopple, J. D. (2006) · Kidney International · doi:10.1038/sj.ki.5001514 · Cited by 905
Steitz, S. A., Speer, M. Y., Curinga, G., Yang, H.-Y., Haynes, P., Aebersold, R., Schinke, T., Karsenty, G., & Giachelli, C. M. (2001) · Circulation Research · doi:10.1161/hh2401.101070 · Cited by 822
Activated Injectable Vitamin D and Hemodialysis Survival: A Historical Cohort Study
Teng, M., Wolf, M., Ofsthun, M. N., Lazarus, J. M., Hernán, M. A., Camargo, C. A., & Thadhani, R. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004070573 · Cited by 782
Larsson, T., Nisbeth, U. L. F., Ljunggren, Ö., Jüppner, H., & Jonsson, K. B. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00328.x · Cited by 689
Fibroblast Growth Factor 23 Is a Counter-Regulatory Phosphaturic Hormone for Vitamin D
Liu, S., Tang, W., Zhou, J., Stubbs, J. R., Luo, Q., Pi, M., & Quarles, L. D. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005111185 · Cited by 642
Self-citationMurshed, M., Harmey, D., Millán, J. L., McKee, M. D., & Karsenty, G. (2005) · Genes & Development · doi:10.1101/gad.1276205 · Cited by 601
Sitara, D., Razzaque, M. S., Hesse, M., Yoganathan, S., Taguchi, T., Erben, R. G., J+APw-ppner, H., & Lanske, B. (2004) · Matrix Biology · doi:10.1016/j.matbio.2004.09.007 · Cited by 542
An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia
Benet-Pagès, A., Orlik, P., Strom, T. M., & Lorenz-Depiereux, B. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi034 · Cited by 507
Pathogenic role of Fgf23 in Hyp mice
Liu, S., Zhou, J., Tang, W., Jiang, X., Rowe, D. W., & Quarles, L. D. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00008.2006 · Cited by 495
Self-citationCollins, A. J., Kasiske, B., Herzog, C., Chavers, B., Foley, R., Gilbertson, D., Grimm, R., Liu, J., Louis, T., Manning, W., et al. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.10.009 · Cited by 461
Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism
Sprague, S. M., Llach, F., Amdahl, M., Taccetta, C., & Batlle, D. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00878.x · Cited by 392
Mortality risk among hemodialysis patients receiving different vitamin D analogs
Tentori, F., for the Medical Directors of Dialysis Clinic Inc., Hunt, W. C., Stidley, C. A., Rohrscheib, M. R., Bedrick, E. J., Meyer, K. B., Johnson, H. K., & Zager, P. G. (2006) · Kidney International · doi:10.1038/sj.ki.5001868 · Cited by 391
Serum FGF23 Levels in Normal and Disordered Phosphorus Homeostasis
Weber, T. J., Liu, S., Indridason, O. S., & Quarles, L. D. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.7.1227 · Cited by 354
Self-citationShoji, T., Shinohara, K., Kimoto, E., Emoto, M., Tahara, H., Koyama, H., Inaba, M., Fukumoto, S., Ishimura, E., Miki, T., et al. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg513 · Cited by 351
Razzaque, M. S., Sitara, D., Taguchi, T., St‐Arnaud, R., & Lanske, B. (2006) · The FASEB Journal · doi:10.1096/fj.05-5432fje · Cited by 346
Vitamin D and calcium deficits predispose for multiple chronic diseases
Peterlik, M., & Cross, H. S. (2005) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2005.01487.x · Cited by 339
Shigematsu, T., Kazama, J. J., Yamashita, T., Fukumoto, S., Hosoya, T., Gejyo, F., & Fukagawa, M. (2004) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.04.029 · Cited by 326
Jono, S., Nishizawa, Y., Shioi, A., & Morii, H. (1998) · Circulation · doi:10.1161/01.cir.98.13.1302 · Cited by 294
Determinants of progressive vascular calcification in haemodialysis patients
Chertow, G. M., Raggi, P., Chasan-Taber, S., Bommer, J., Holzer, H., & Burke, S. K. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh125 · Cited by 279
Hesse, M., Fröhlich, L. F., Zeitz, U., Lanske, B., & Erben, R. G. (2007) · Matrix Biology · doi:10.1016/j.matbio.2006.10.003 · Cited by 198
Sitara, D., Razzaque, M. S., St‐Arnaud, R., Huang, W. Y., Taguchi, T., Erben, R. G., & Lanske, B. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.060329 · Cited by 153
Ichikawa, S., Lyles, K. W., & Econs, M. J. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2302 · Cited by 152
Fibroblast Growth Factor-23 Mutants Causing Familial Tumoral Calcinosis Are Differentially Processed
Larsson, T. E., Davis, S. I., Garringer, H. J., Mooney, S. D., Draman, M. S., Cullen, M. J., & White, K. E. (2005) · Endocrinology · doi:10.1210/en.2005-0431 · Cited by 132
Reversibility of Calcitriol-Induced Medial Artery Calcification in Rats With Intact Renal Function
Bas, A., Lopez, I., Pérez, J., Rodríguez, M., & Aguilera‐Tejero, E. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.051211 · Cited by 126
Frishberg, Y., Topaz, O., Bergman, R., Behar, D. M., Fisher, D., Gordon, D., Richard, G., & Sprecher, E. (2004) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0610-8 · Cited by 116
Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3
Haffner, D., Hocher, B., Müller, D. N., et al. (2005) · Journal of Hypertension · doi:10.1097/01.hjh.0000166849.72721.1c · Cited by 115
Role of Matrix Extracellular Phosphoglycoprotein in the Pathogenesis of X-Linked Hypophosphatemia
Liu, S., Brown, T. A., Zhou, J., Xiao, Z.-S., Awad, H. A., Guilak, F., & Quarles, L. D. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004121060 · Cited by 92
Self-citationOverexpression of Phex in Osteoblasts Fails to Rescue the Hyp Mouse Phenotype
Liu, S., Guo, R., Tu, Q., & Quarles, L. D. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m107707200 · Cited by 91
Self-citationArad, Y., Spadaro, L. A., Roth, M., Scordo, J., Goodman, K., Sherman, S., Lerner, G., Newstein, D., & Guerci, A. D. (1998) · Coronary Artery Disease · doi:10.1097/00019501-199809080-00007 · Cited by 76
Vascular Calcification in Dialysis Patients
Humoud, H. A., Al‐Hilali, N., Ahmad, A., Ninan, V. T., Nampoory, M. R. N., Rizk, A. M., Ali, J. H., & Johny, K. V. (2005) · Transplantation Proceedings · doi:10.1016/j.transproceed.2005.11.041 · Cited by 25
Whole-mount procedures for simultaneous visualization of nerves, neurons, cartilage and bone
Rosa‐Molinar, E., Proskocil, B. J., Ettel, M. G., & Fritzsch, B. (1999) · Brain Research Protocols · doi:10.1016/s1385-299x(99)00007-0 · Cited by 15
Cited by
Fibroblast Growth Factor 23 and Mortality among Patients Undergoing Hemodialysis
Gutiérrez, O. M., Mannstadt, M., Isakova, T., Rauh-Hain, J. A., Tamez, H., Shah, A., Smith, K., Lee, H., Thadhani, R., Jüppner, H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706130 · Cited by 1,727
The parathyroid is a target organ for FGF23 in rats
Ben-Dov, I. Z., Galitzer, H., Lavi-Moshayoff, V., Goetz, R., Kuro-o, M., Mohammadi, M., Sirkis, R., Naveh-Many, T., & Silver, J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32409 · Cited by 951
Klotho Deficiency Causes Vascular Calcification in Chronic Kidney Disease
Hu, M. C., Shi, M., Zhang, J., Quiñones, H., Griffith, C., Kuro-o, M., & Moe, O. W. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009121311 · Cited by 926
Regulation of Phosphate Homeostasis by PTH, Vitamin D, and FGF23
Bergwitz, C., & Jüppner, H. (2010) · Annual Review of Medicine · doi:10.1146/annurev.med.051308.111339 · Cited by 741
The Klotho proteins in health and disease
Kuro-o, M. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0078-3 · Cited by 707
Metadata
- Authors
- Stubbs, J. R., Liu, S., Tang, W., Zhou, J., Wang, Y., Yao, X., & Quarles, L. D.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2007-07
- Volume
- 18
- Issue
- 7
- Pages
- 2116-2124
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2150341551
- Cited by
- 276
- References
- 39
- FWCI
- 14.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.